Home monitoring of kidney function in cancer patients: assessing acceptability and clinical benefit

Not Applicable

• Conditions: ephro-oncology; Cancer

• Registration Number: ISRCTN11076307
• Lead Sponsor: niversity of Manchester

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-30
• Last Update Posted: 1 March 2021
• Study Completion: 2022-03-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Provision of signed and dated, written informed consent prior to participation in the study
2. Aged at least 18 years
3. Receiving treatment for cancer with potentially nephrotoxic anti-cancer therapies (according to the judgement of the CI)
4. Individuals whose medical team consider to be medically stable and able enough to take part or designated carer who would be able to perform the tasks required
5. Willingness and ability to self-monitor creatinine using device at home or have a designated carer who would be able to perform the tasks required. Part A device will be the NovaBiomedical StatSensor®
6. Access to smartphone and willingness to use, without reimbursement of any potential additional costs incurred, their iOS/Android device for the collection and transmission of information

Exclusion Criteria

1. Being an employee, or closely linked with an employee, of the device company
2. Judgment by the Investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements
3. WHO performance status > 2
4. Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified